检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:周颖[1] 陈虹[1] 马建慧[1] 祝世发[1] 刘小莉[1]
出 处:《石河子大学学报(自然科学版)》2006年第6期705-708,共4页Journal of Shihezi University(Natural Science)
基 金:新疆生产建设兵团医药专项资助项目(NO:04GG24)
摘 要:为探讨复方苦豆子(CK)对肾性高血压大鼠(RHR)左室肥厚(LVH)及血浆血管紧张素II(AngII)的影响,建立了二肾一夹型高血压大鼠模型(2KⅠC-RHR),选取造模成功的大鼠57只,随机分为5组:模型组(Mod组),CK高、中、低剂量组(H、M、L组)和卡托普利组(Cap组),另取10只作为假手术组(Sham组)。每日灌药1次,连续8周。根据体重随时调整给药量。观察药物对模型动物左室肥厚指数(LVHI)及AngⅡ影响。结果表明:1)CK长期给药能明显降低模型动物的LVHI,H、M组与Mod组相比均有显著性差异(P<0.01),L组也有下降趋势,但无统计学意义。2)CK能降低模型动物血浆AngⅡ水平,与Mod组相比,各给药组均有显著性差异(P<0.01),以H组下降最为明显。这表明CK对RHR的心脏重塑有一定的防治作用,其机制可能与抑制肾素-血管紧张素系统(RAS)活性有关。To investigate the effects of compound kudouzi(CK) on left ventricular hypertrophy(LVH) and AnglI in plasm in renal hypertensive rats (RHR),and analyze the possible mechanism. Methods:2-kidney 1-clip(2K Ⅰ C) renovaseular hypertension was induced in male wister rots.57 RHR were randomly divided into 5 groups as follows: model group(n = 11 ), high dose of CK group(H groop), middle dose of CK group(M group, n = 12), low dose of CK group(L group) and eaptopril group( Cap group, n = 10), in addition , sham-operated group(sham group) were fed with drinking water too. All rats were treated once a day for 8 weeks, and the volumes of the drug were adjusted any time according to the changes of their weight. The left ventricular hypertrophy index(LVHI) and the levels of angiotension Ⅱ (AngⅡ) were measured. Results: Compared with model group, the LVHI were significantly decreased in H and M groups. L group had the tendency of decline, but had no significance. The concentration of AngII in plasma of H group is much lower than in moddle group( P 〈 0.01 ). Conlusion: Chronic use of CK can inhibit and reverse ventricular hypertropy, and the effect is relativdy dosedependent. Decreasing activity of RAS probably is one of the mechanisms.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15